Tag Archives: Rockefeller University
← Older postsDecibel Therapeutics Strikes a Balance, Adding Regenerative Med Focus
Decibel Therapeutics emerged four years ago aiming to build a pipeline of medicines for various forms of hearing loss. One of those drugs is in the clinic. Others were shelved. And some of the company’s resources are now focusing on regenerative therapies addressing the inner ear. The recent pipeline changes are accompanied by a corporate […]
Posted in Boston, Boston blog main, Boston top stories, National blog main, National top stories, New York blog main | Tagged Adeno-Associated Virus, bilateral vestibuloapthy, Biotech, cancer, Chemotherapy, cisplatin, clinical trials, Decibel Therapeutics, Frequency Therapeutics, Gene Therapy, Hearing Loss, Joe Burns, Laurence Reid, Life Sciences, Regenerative Medicine, Regeneron Pharmaceuticals, Rockefeller University, startups, Steven Holtzman, Third Rock Ventures | Comments Off on Decibel Therapeutics Strikes a Balance, Adding Regenerative Med FocusNY’s Research Institutions Must Keep Working Together in ‘19
[Corrected, 1/7/19, 5:15 pm. See below.] [Editor’s Note: Euan Robertson, the Director of Strategic Planning & Special Projects at Columbia Technology Ventures, co-wrote this article.] It is a commonly held belief that academic research institutions, including those in New York City, are fierce competitors. In some ways, that may be true: Universities battle with each […]
Posted in Boston Xcon, Boulder/Denver Xcon, Detroit Xcon, Indiana Xcon, National Xcon, New York, New York Xcon, Raleigh-Durham Xcon, San Diego Xcon, San Francisco Xcon, Seattle Xcon, Texas Xcon, Wisconsin Xcon | Tagged Applied Therapeutics, BioMedX, Biotech, Columbia University, Columbia World Projects, Cornell University, CyberNYC, deals, Kallyope, Lee Bollinger, Life Sciences, Memorial Sloan-Kettering Cancer Center, National Institutes of Health, National Science Foundation, New York City Economic Development Corp., New York Genome Center, New York State Energy Reearch and Development Authority, NYC Media Lab Combine, NYC rLab, NYU, PowerBridgeNY, Quentis Therapeutics, Rgenix, Robertson Fund, Rockefeller University, startups, Tara Biosystems, Tech, The City University of New York, Translational Research Accelerator, Tri-Institutional Therapeutics Discovery Institute, VC, Yearend2018 | Comments Off on NY’s Research Institutions Must Keep Working Together in ‘19Bio Roundup: Moderna’s Billions, Cytokine Bets, Shire Acquired & More
Cytokine therapies for cancer aren’t new but they are attracting renewed interest. Some pharmaceutical companies see drug combinations using cytokines as a way to broaden the reach of immunotherapy, which still doesn’t work for the majority of cancer patients. This week, Eli Lilly (NYSE: LLY) showed how much it believes in cytokines. The Indianapolis drug maker […]
Posted in Boston blog main, Boston top stories, Boulder/Denver blog main, Boulder/Denver top stories, Detroit blog main, Detroit top stories, Indiana blog main, Indiana top stories, National, National blog main, National top stories, New York blog main, New York top stories, Raleigh-Durham blog main, Raleigh-Durham top stories, San Diego blog main, San Diego top stories, San Francisco blog main, San Francisco top stories, Seattle blog main, Seattle top stories, Texas blog main, Texas top stories, Wisconsin blog main, Wisconsin top stories | Tagged Akcea Therapeutics, Akili Interactive Labs, Alder Biopharmaceuticals, andexanet alfa, Armo Biosciences, Ascletis Pharma, atezolizumab, Autolus Therapeutics, Biotech, Broad Institute, California Stem Cell Treatment Center, cancer, cancer immunotherapy, CAR-T, clinical trials, cobimetinib, CRISPR, cytokines, deals, Donald Trump, Eli Lilly, eptinezumab, Escient Pharmaceuitcals, Evelo Biosciences, Exelixis, Feng Zhang, Gene Therapy, Genentech, geneSight, George Church, Harvard University, initial public offering, investing, Ionis Pharmaceuticals, IPO, Joe Jimenez, Life Sciences, Lodo Therapeutics, Luna DNA, Michael Cohen, Microbiome, Migraine, ModeRNA Therapeutics, Novartis, Pancreatic Cancer, Portola Pharmaceuticals, Rejuvenate Bio, Roche, Rockefeller University, Shire, startups, Takeda Pharamceutical, U.S. Stem Cell, Vas Narasimhan, volanesorsen | Comments Off on Bio Roundup: Moderna’s Billions, Cytokine Bets, Shire Acquired & MoreVinod Khosla on A.I., Health, and the Future of Working (or Not)
Entrepreneur-turned-venture capitalist Vinod Khosla made big headlines almost six years ago when he wrote a blog post called “Do We Need Doctors or Algorithms?” In it, he said medicine needed to be reinvented and he predicted a new era in which artificial intelligence might replace most of the functions that doctors do now—and do it […]
Posted in Boston blog main, Boston top stories, Boulder/Denver blog main, Boulder/Denver top stories, Detroit blog main, Detroit top stories, Indiana blog main, Indiana top stories, National blog main, National top stories, New York blog main, New York top stories, Raleigh-Durham blog main, Raleigh-Durham top stories, San Diego blog main, San Diego top stories, San Francisco, San Francisco blog main, San Francisco top stories, Seattle blog main, Seattle top stories, Texas blog main, Wisconsin blog main, Wisconsin top stories | Tagged 16 Tech innovation district, A.I., AliveCor, AlphaGo, Computing, deals, Deep Blue, DeepMind, Economy, Elon Musk, Ginger.io, google, health, Health IT, Healthtech, IBM, information technology, Jobs, Khosla Ventures, Life Sciences, Marc Tessier-Lavigne, Medicine, NNT, Number Needed to Treat, people, Robotics, RoboticsAI, Rockefeller University, Stanford University, startups, Tech, Technology, Tesla, VC, Vinod Khosla, Watson Health, xperience, Zebra Medical Vision | Comments Off on Vinod Khosla on A.I., Health, and the Future of Working (or Not)Near The East River, Plans Emerge For NY’s Next Life Science Center
At a time when biotech incubators and shared spaces are beginning to multiply in Manhattan, work on what could rank among the city’s largest biotech centers—if it can all come together—is just getting underway. According to Paul Wexler, a longtime healthcare-focused real estate broker, construction should begin next year on what is being called the […]
Posted in Boston blog main, National blog main, National top stories, New York, New York blog main, New York top stories, San Francisco blog main | Tagged Adam Goulburn, Alexandria Center for Life Science, Bill de Blasio, Biotech, Con Edison, Hudson Research Center, JDS Development, Kallyope, Life Sciences, LifeSci NYC, Lux Capital, New York City Economic Development Corp., New York Life Sciences and Biotechnology Center, NYU Langone Medical Center, Paul Wexler, Real Estate, Rockefeller University, Sheldon Solow, Silverstein Properties, Taconic Investment Partners, Weill Cornell Medicine | Comments Off on Near The East River, Plans Emerge For NY’s Next Life Science CenterOn the Hudson, Two Developers Open NYC’s Latest Bio Startup Space
Two real estate developers, Taconic Investment Partners and Silverstein Properties, have unveiled plans to bring about 150,000 square feet of new wet lab space online on the West Side of Manhattan, the latest effort in an ongoing quest in New York City to provide startup biotech companies a local home to form and grow. Taconic […]
Posted in Boston blog main, National blog main, National top stories, New York, New York blog main, New York top stories, San Francisco blog main | Tagged Alexandria Real Estate Equities, BioBAT, Biotech, Eva Cramer, Harlem Biospace, JLabs, Johnson & Johnson, LaunchLabs, Life Sciences, LifeSci NYC, Matthew Weir, New York biotech, New York Genome Center, NYU Langone Medical Center, Rockefeller University, Silverstein Properties, startups, SUNY Downstate Medical Center, Taconic Investment Partners, VC, Weill Cornell Medical Center | Comments Off on On the Hudson, Two Developers Open NYC’s Latest Bio Startup SpaceStalled or Rising Momentum? New York Wrestles With Its Biotech Future
[Updated, 6:25 a.m. ET, see below] New York City and state governments have finally put big dollars behind local development of the life sciences industry. But lots of cash is no guarantee of success, as panelists kicking off the annual NewYorkBio conference made clear Tuesday. “The question is, where are we as an industry, and […]
Posted in Boston blog main, National blog main, National top stories, New York, New York blog main, New York top stories, San Francisco blog main, San Francisco top stories, Seattle blog main, Seattle top stories | Tagged Accelerate NY Seed Fund, Accelerator Corp., Adam Goulburn, Alexandria Real Estate Equities, ARCH Venture Partners, BioLabs New York, Doug Thiede, Empire State Development, events, Flagship Ventures, Genentech, Genetics Institute, Genzyme, Highline Therapeutics, JLabs, Johnson & Johnson, LaunchLabs, Life Sciences, LifeSci NYC, Lux Capital, Malcolm Gladwell, Maria Gotsch, Maria Mitchell, Michael Aberman, Nadim Shohdy, New York biotech, New York City Economic Development Corp., New York Genome Center, New York State Empire State Development Corp., NewYorkBio, Nicole McKnight, NYU Langone Medical Center, Partnership Fund for New York City, people, Pfizer, Regeneron Pharmaceuticals, Rick Lifton, Rockefeller University, Ryan Birchmeier, The New York Stem Cell Foundation, Uwe Schoenbeck, Versant Ventures | Comments Off on Stalled or Rising Momentum? New York Wrestles With Its Biotech FutureNY Bio Surge Continues as De Blasio Unveils $500M, 10-Year Life Sci Plan
[Updated w/comments, new information, 3:45 p.m. ET, see below] Over the last two days, city and state governments in New York have combined to commit a total of $1.15 billion to the development of the life sciences industry in the Empire State, the largest biotech bet in its history. Today is New York City’s turn. […]
Posted in Boston blog main, National blog main, National top stories, New York, New York blog main, New York top stories, San Francisco blog main | Tagged Accelerator Corp., Alexandria Center for Life Science, ARCH Venture Partners, Bay City Capital, Bill de Blasio, Biogen, Biotech, Bridge Medicines, Deerfield Management, Eli Lilly, events, Flagship Ventures, Gillian Small, Harold Varmus, Laurie Glimcher, Lenzie Harcum, Life Sciences, Marc Tessier-Lavigne, National Cancer Institute, New York City Economic Development Corp., New York Genome Center, NYU Langone Medical Center, people, Richard Lifton, Roche, Rockefeller University, startups, Takeda, Tri-Institutional Therapeutics Discovery Institute, Versant Ventures, Vertex Pharmaceuticals, Vicki Sato, Weill Cornell Medicine | Comments Off on NY Bio Surge Continues as De Blasio Unveils $500M, 10-Year Life Sci PlanNew York Institutions, VCs Team up to Build Drug Discovery “Bridge”
[Updated, 11:10 a.m. ET, see below] New York biotech has historically lagged behind more established life sciences hubs like Boston and San Francisco, but collaborations between its research institutions have helped the city start to move forward. Another step in that direction was taken this morning, with the launch of what’s being called Bridge Medicines. […]
Posted in Boston blog main, National blog main, National top stories, New York, New York blog main, New York top stories, San Francisco blog main | Tagged Accelerator Corp., ARCH Venture Partners, Biotech, Bridge Medicines, deals, Flagship Ventures, Life Sciences, Mike Foley, new york, New York Genome Center, Niemann-Pick type C disease, Rockefeller University, startups, Takeda, Tri-Institutional Therapeutics Discovery Institute, Tuberculosis, Versant Ventures, Weill Cornell Medical College | Comments Off on New York Institutions, VCs Team up to Build Drug Discovery “Bridge”Bio Roundup: CAR-T & Migraine Races, Intra-Cellular, Rockefeller & More
The presidential race captivated millions of TV viewers this week as the first debate took place in Hofstra. But biotech watchers had other races on their mind. Who will be first to market with a new type of cancer treatment known as CAR-T? Who will break free of the pack of companies developing drugs meant […]
Posted in Boston blog main, Boulder/Denver blog main, Detroit blog main, Indiana blog main, National, National blog main, National top stories, New York blog main, Raleigh-Durham blog main, San Diego blog main, San Francisco blog main, Seattle blog main, Texas blog main, Wisconsin blog main | Tagged Alder Biopharmaceuticals, Alnylam Pharmaceuticals, Amgen, Array Biopharma, Arrowhead Pharmaceuticals, Aura Biosciences, Avalon Ventures, Bluebird, bortezomib, cancer immunotherapy, CAR-T, Carfilzomib, Caribou Biosciences, Catabasis Pharmaceuticals, Celgene, Constellation Pharmaceuticals, deals, Duchenne Muscular Dystrophy, Eli Lilly, erenumab, Fortis Therapeutics, Genital Herpes, Genocea Biosciences, Genzyme, Henri Termeer, ImmunoGen, Intra-Cellular Therapies, Kite Pharma, Kyprolis, Life Sciences, Marc Tessier-Lavigne, Medigene, Migraine, Multiple Sclerosis, Onyx Pharmaceuticals, Rachel Hurwitz, Richard Lifton, Rockefeller University, Roundup, Sarepta Therapeutics, startups, T-cells, Teva Pharmaceutical, UCSF, Velcade, Wendell Lim, Yale University | Comments Off on Bio Roundup: CAR-T & Migraine Races, Intra-Cellular, Rockefeller & More← Older postsArchives
- October 2020
- September 2020
- August 2020
- July 2020
- June 2020
- May 2020
- April 2020
- March 2020
- February 2020
- January 2020
- December 2019
- November 2019
- October 2019
- September 2019
- August 2019
- July 2019
- June 2019
- May 2019
- April 2019
- March 2019
- February 2019
- January 2019
- December 2018
- November 2018
- October 2018
- September 2018
- August 2018
- July 2018
- June 2018
- May 2018
- April 2018
- March 2018
- February 2018
- January 2018
- December 2017
- November 2017
- October 2017
- September 2017
- August 2017
- July 2017
- June 2017
- May 2017
- April 2017
- March 2017
- February 2017
- January 2017
- December 2016
- November 2016
- October 2016
- September 2016
- August 2016
- July 2016
- June 2016
- May 2016
- April 2016
- March 2016
- February 2016
- January 2016
- December 2015
- November 2015
- October 2015
- September 2015
- August 2015
- July 2015
- June 2015
- May 2015
- April 2015
- March 2015
- February 2015
- January 2015
- December 2014
- November 2014
- October 2014
- September 2014
- August 2014
- July 2014
- June 2014
- May 2014
- April 2014
- March 2014
- February 2014
- January 2014
- December 2013
- November 2013
- October 2013
- September 2013
- August 2013
- July 2013
- June 2013
- May 2013
- April 2013
- March 2013
- February 2013
- January 2013
- December 2012
- November 2012
- October 2012
- September 2012
- August 2012
- July 2012
- June 2012
- May 2012
- April 2012
- March 2012
- February 2012
- January 2012
- December 2011
- November 2011
- October 2011
- September 2011
- August 2011
- July 2011
- June 2011
- May 2011
- April 2011
- March 2011
- February 2011
- January 2011
- December 2010
- November 2010
- October 2010
- September 2010
- August 2010
- July 2010
- June 2010
- May 2010
- April 2010
- March 2010
- February 2010
- January 2010
- December 2009
- November 2009
- October 2009
- September 2009
- August 2009
- July 2009
- June 2009
- May 2009
- April 2009
- March 2009
- February 2009
- January 2009
- December 2008
- November 2008
- October 2008
- September 2008
- August 2008
- July 2008
- June 2008
- May 2008
- April 2008
- March 2008
- February 2008
- January 2008
- December 2007
- November 2007
- October 2007
- September 2007
- August 2007
- July 2007
- June 2007
- May 2007
- April 2007
- March 2007
- January 2007
- December 2006
- November 2006
- October 2006
- September 2006
- August 2006
- July 2006
- June 2006
- April 2006
- March 2006
- February 2006
- January 2006
- December 2005
- October 2005
- September 2005
- August 2005
- July 2005
- June 2005
- May 2005
- April 2005
- March 2005
- February 2005
- January 2005
- December 2004
- September 2004
- June 2004
- May 2004
- March 2004
- February 2004
- January 2004
- December 2003
- June 2003
- May 2003
- March 9
Meta